Related Experiment Video
Updated: May 17, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Mechanisms by which chromobox homolog 4 regulates angiogenic mimicry and angiogenic activity in osteosarcoma
Haoran Gui1, Bo Li2
1Department of Emergency, Yantaishan Hospital, Yantai, 264000, Shandong, China.
Abstract:
Osteosarcoma (OS) is a very aggressive malignant neoplasm characterized by significant metastases and a deficiency of treatment targets. Therefore, it is urgent to find new therapeutic mechanisms and targets for OS. We assessed the capability of chromobox homolog 4 (CBX4) to modulate OS growth using in vivo and in vitro dual tests utilizing short hairpin RNA technology, 3-dimensional tumor sphere building, immunofluorescence co-localization, and other biotechnological methods. Our findings indicated that CBX4 was overexpressed in OS tissues, and the silencing of CBX4 markedly reduced OS cell proliferation, migration, and invasion. CBX4 modulates vasculogenic mimicry through its influence on yes1 associated transcriptional regulator (YAP1) and neuropilin-2/vascular endothelial growth factor A (NRP2/VEGFA) pathway, hence promoting angiogenic activity, a mechanism perhaps linked to CBX4's role in regulating mitochondrial autophagy. CBX4 affects vasculogenic mimicry by regulating the YAP1 and NRP2/VEGFA pathways and promotes the OS process. CBX4 may serve as a novel biomarker for OS, potentially offering innovative approaches for early diagnosis and tailored therapy of OS. SIGNIFICANCE STATEMENT: Osteosarcoma (OS) is a very aggressive malignant neoplasm characterized by significant metastases and a deficiency of treatment targets. Therefore, it is urgent to find new therapeutic mechanisms and targets for OS. Chromobox homolog 4 may serve as a novel biomarker for OS, potentially offering innovative approaches for early diagnosis and tailored therapy of OS.
Insights
Chromobox homolog 4 (CBX4) is overexpressed in osteosarcoma (OS) and drives tumor growth and metastasis. Targeting CBX4 offers a potential new therapeutic strategy and biomarker for this aggressive bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Osteosarcoma (OS) is a highly aggressive bone cancer with limited treatment options and a propensity for metastasis.
- There is an urgent need for novel therapeutic targets and mechanisms to combat OS progression.
Purpose of the Study:
- To investigate the role of Chromobox homolog 4 (CBX4) in the growth and progression of osteosarcoma.
- To explore CBX4 as a potential therapeutic target and diagnostic biomarker for OS.
Main Methods:
- Utilized in vivo and in vitro models of OS.
- Employed short hairpin RNA (shRNA) technology for gene silencing.
- Performed 3D tumor sphere assays, immunofluorescence, and other biotechnological techniques.
Main Results:
- CBX4 was found to be overexpressed in OS tissues.
- Silencing CBX4 significantly inhibited OS cell proliferation, migration, and invasion.
- CBX4 was shown to modulate vasculogenic mimicry via the YAP1 and NRP2/VEGFA pathways, promoting angiogenesis.
Conclusions:
- CBX4 plays a critical role in promoting OS growth, invasion, and angiogenesis.
- CBX4 represents a promising novel biomarker for early diagnosis and a potential therapeutic target for osteosarcoma.
- Targeting CBX4 may offer innovative strategies for tailored OS therapy.
Related Concept Videos
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
TGF - β Signaling Pathway
Hedgehog Signaling Pathway

